Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H P Hartung

Showing results (1-10 of 426) with videos related to

Pageof 43
Sort By:
Wiener Medizinische Wochenschrift (1946)|January 1, 1996
[Pathogenesis of multiple sclerosis: status of research]H P Hartung
FEBS Letters|August 22, 1983
Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7H P Hartung
Journal of Neurology, Neurosurgery, and Psychiatry|March 20, 1999
Infections and the Guillain-Barré syndromeH P Hartung
Cellular Immunology|July 1, 1986
Calcium fluxes and calmodulin inhibitors in macrophage activationH P Hartung
European Journal of Pharmacology|July 15, 1983
Leukotriene C4 (LTC4) elicits a respiratory burst in peritoneal macrophagesH P Hartung
Acta Neurologica Belgica|January 1, 1994
Experimental allergic neuritis and Guillain-Barré syndrome: immune mechanisms. A short reviewH P Hartung
Medizinische Klinik (Munich, Germany : 1983)|October 18, 2001
[Current status of interferon beta-1b in multiple sclerosis therapy]H P Hartung
Current Opinion in Neurology|June 1, 1995
Pathogenesis of inflammatory demyelination: implications for therapyH P Hartung
Der Nervenarzt|September 26, 2009
[Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis]H-P Hartung
Brain, Behavior, and Immunity|December 1, 1988
Activation of macrophages by neuropeptidesH P Hartung
Pageof 43

Showing results (1-10 of 426) with videos related to

Sort By:
Pageof 43
Wiener Medizinische Wochenschrift (1946)|January 1, 1996
[Pathogenesis of multiple sclerosis: status of research]H P Hartung
FEBS Letters|August 22, 1983
Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7H P Hartung
Journal of Neurology, Neurosurgery, and Psychiatry|March 20, 1999
Infections and the Guillain-Barré syndromeH P Hartung
Cellular Immunology|July 1, 1986
Calcium fluxes and calmodulin inhibitors in macrophage activationH P Hartung
European Journal of Pharmacology|July 15, 1983
Leukotriene C4 (LTC4) elicits a respiratory burst in peritoneal macrophagesH P Hartung
Acta Neurologica Belgica|January 1, 1994
Experimental allergic neuritis and Guillain-Barré syndrome: immune mechanisms. A short reviewH P Hartung
Medizinische Klinik (Munich, Germany : 1983)|October 18, 2001
[Current status of interferon beta-1b in multiple sclerosis therapy]H P Hartung
Current Opinion in Neurology|June 1, 1995
Pathogenesis of inflammatory demyelination: implications for therapyH P Hartung
Der Nervenarzt|September 26, 2009
[Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis]H-P Hartung
Brain, Behavior, and Immunity|December 1, 1988
Activation of macrophages by neuropeptidesH P Hartung
Pageof 43